JP2019528779A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019528779A5 JP2019528779A5 JP2019524501A JP2019524501A JP2019528779A5 JP 2019528779 A5 JP2019528779 A5 JP 2019528779A5 JP 2019524501 A JP2019524501 A JP 2019524501A JP 2019524501 A JP2019524501 A JP 2019524501A JP 2019528779 A5 JP2019528779 A5 JP 2019528779A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- amino acid
- acid sequence
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610584242.9 | 2016-07-22 | ||
| CN201610584242.9A CN107446045A (zh) | 2016-07-22 | 2016-07-22 | 一种抗her2的抗体、其药物组合物及用途 |
| US15/461,732 | 2017-03-17 | ||
| US15/461,732 US9745382B1 (en) | 2016-07-22 | 2017-03-17 | Bispecific anti-HER2 antibody |
| PCT/CN2017/093816 WO2018014864A1 (en) | 2016-07-22 | 2017-07-21 | Bispecific anti-her2 antibody |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019528779A JP2019528779A (ja) | 2019-10-17 |
| JP2019528779A5 true JP2019528779A5 (enExample) | 2019-12-12 |
| JP6823175B2 JP6823175B2 (ja) | 2021-01-27 |
Family
ID=59654118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019524501A Expired - Fee Related JP6823175B2 (ja) | 2016-07-22 | 2017-07-21 | 二重特異性抗ｈｅｒ２抗体 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9745382B1 (enExample) |
| EP (1) | EP3487888A4 (enExample) |
| JP (1) | JP6823175B2 (enExample) |
| CN (2) | CN107446045A (enExample) |
| AU (1) | AU2017298251B2 (enExample) |
| CA (1) | CA3031330C (enExample) |
| WO (1) | WO2018014864A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019094608A1 (en) | 2017-11-08 | 2019-05-16 | Denali Therapeutics Inc. | Anti-bace1 antibodies and methods of use thereof |
| FI3765525T3 (fi) | 2018-03-13 | 2023-10-16 | Zymeworks Bc Inc | Biparatooppisen her2-vasta-aineen ja lääkkeen konjugaatteja ja käyttömenetelmiä |
| WO2020000452A1 (zh) * | 2018-06-29 | 2020-01-02 | 深圳市博奥康生物科技有限公司 | 一种靶向人NGL基因的新型RNAi干扰片段、RNAi载体及其制备方法和其应用 |
| WO2020000458A1 (zh) * | 2018-06-29 | 2020-01-02 | 深圳市博奥康生物科技有限公司 | 一种特异靶向人NGL基因的gRNA导向序列及其应用 |
| EP3840781A1 (en) * | 2018-08-22 | 2021-06-30 | Denali Therapeutics Inc. | Anti-her2 polypeptides and methods of use thereof |
| CN113166765B (zh) * | 2018-08-29 | 2024-03-26 | 联合生物制药股份有限公司 | 去岩藻醣基化抗体及其制造 |
| EP3988574A4 (en) * | 2019-02-03 | 2022-10-12 | Shanghai Bao Pharmaceuticals Co., Ltd. | AGAINST HER2 BI-SPECIFIC ANTIBODIES AND THEIR USE |
| US20210238305A1 (en) * | 2019-03-01 | 2021-08-05 | Remegen Co., Ltd. | Antibody for her2 concomitant diagnosis immunohistochemical detection and application thereof |
| CN111848805B (zh) * | 2019-04-30 | 2023-05-05 | 非同（成都）生物科技有限公司 | 用于肿瘤免疫治疗的具有双Her2位点的双特异性抗体 |
| CN114040928A (zh) * | 2020-03-27 | 2022-02-11 | 江苏康宁杰瑞生物制药有限公司 | Her2双特异性抗体的有效剂量 |
| WO2021219046A1 (zh) * | 2020-04-30 | 2021-11-04 | 正大天晴药业集团股份有限公司 | 靶向her2的抗原结合构建体及用途 |
| EP4161566A4 (en) * | 2020-06-03 | 2024-06-12 | The Broad Institute, Inc. | ANTAGONISTIC BIPARATOPIC ANTIBODIES SPECIFICALLY BINDING FIBROBLAST GROWTH FACTOR RECEPTOR 2 AND METHODS OF USE THEREOF |
| EP4190818A4 (en) * | 2020-07-28 | 2024-08-07 | Bio-Thera Solutions, Ltd. | ANTI-HER2 ANTIBODY AND ITS USE |
| CN119792564A (zh) | 2020-08-13 | 2025-04-11 | 正大天晴药业集团股份有限公司 | 抗体药物偶联物 |
| CN114539413A (zh) * | 2020-11-25 | 2022-05-27 | 三生国健药业（上海）股份有限公司 | 结合her2的多价双特异性抗体、其制备方法和用途 |
| US20240307551A1 (en) * | 2021-07-05 | 2024-09-19 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd. | Antibody-drug conjugate and application thereof |
| CN113817065B (zh) * | 2021-09-06 | 2023-04-18 | 深圳市乐土生物医药有限公司 | 一种抗her2的多肽及其用途 |
| JP2025525969A (ja) * | 2022-08-05 | 2025-08-07 | ヤンセン バイオテツク，インコーポレーテツド | 脳腫瘍を治療するためのｃｄ９８結合構築物 |
| CA3263784A1 (en) * | 2022-08-05 | 2024-02-08 | Janssen Biotech, Inc. | TRANSFERRIN RECEPTOR BINDING PROTEINS FOR THE TREATMENT OF BRAIN TUMORS |
| JP2026504928A (ja) * | 2023-01-20 | 2026-02-10 | ワシントン・ユニバーシティ | Ｌｉｌｒｂ４／ｉｌｔ３アンタゴニスト組成物およびその使用方法 |
| WO2024183622A1 (zh) * | 2023-03-03 | 2024-09-12 | 盛禾(中国)生物制药有限公司 | 一种抗her2抗体在制备治疗癌症的药物中的用途 |
| WO2024183623A1 (zh) * | 2023-03-03 | 2024-09-12 | 盛禾(中国)生物制药有限公司 | 一种抗her2抗体在制备治疗癌症的药物中的用途 |
| WO2025124463A1 (zh) * | 2023-12-12 | 2025-06-19 | 上海宝济药业股份有限公司 | 抗her2的双特异性抗体及其应用 |
| CN118206662A (zh) * | 2024-05-14 | 2024-06-18 | 中国人民解放军军事科学院军事医学研究院 | 一种靶向Her2的新型单克隆抗体及其应用 |
| WO2026077405A1 (zh) * | 2024-10-11 | 2026-04-16 | 烟台蓝纳成生物技术股份有限公司 | 一种抗her2抗体、抗体核素偶联物及其应用 |
| CN119462959B (zh) * | 2024-10-24 | 2025-12-19 | 南京元迈细胞生物科技有限公司 | 嵌合抗原受体及其修饰的细胞 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| ATE255131T1 (de) | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
| HUP0600340A3 (en) | 2002-07-15 | 2011-06-28 | Genentech Inc | Methods for identifying tumors that are responsive to treatment with anti-erbb2 antibodies |
| HK1220919A1 (zh) * | 2013-04-05 | 2017-05-19 | F. Hoffmann-La Roche Ag | 抗il-4抗体和双特异性抗体及其用途 |
| EP4570318A3 (en) * | 2013-11-27 | 2025-10-15 | Zymeworks BC Inc. | Bispecific antigen-binding constructs targeting her2 |
| CA2925677A1 (en) | 2013-12-20 | 2015-06-25 | F. Hoffmann-La Roche Ag | Bispecific her2 antibodies and methods of use |
| SG11201608192SA (en) * | 2014-04-11 | 2016-10-28 | Medimmune Llc | Bispecific her2 antibodies |
| CN105017421B (zh) | 2014-04-16 | 2017-12-26 | 中国人民解放军海军总医院 | 一种抗her2双特异性抗体及其制备方法与应用 |
| CN106163558A (zh) * | 2014-04-25 | 2016-11-23 | 豪夫迈·罗氏有限公司 | 用曲妥珠单抗‑mcc‑dm1和帕妥珠单抗治疗早期乳腺癌的方法 |
| CN110655582B (zh) * | 2015-01-08 | 2022-12-16 | 江苏康宁杰瑞生物制药有限公司 | 具有共同轻链的双特异性抗体或抗体混合物 |
-
2016
- 2016-07-22 CN CN201610584242.9A patent/CN107446045A/zh active Pending
-
2017
- 2017-03-17 US US15/461,732 patent/US9745382B1/en not_active Expired - Fee Related
- 2017-07-21 JP JP2019524501A patent/JP6823175B2/ja not_active Expired - Fee Related
- 2017-07-21 EP EP17830498.6A patent/EP3487888A4/en not_active Withdrawn
- 2017-07-21 WO PCT/CN2017/093816 patent/WO2018014864A1/en not_active Ceased
- 2017-07-21 AU AU2017298251A patent/AU2017298251B2/en not_active Ceased
- 2017-07-21 CN CN201780053734.8A patent/CN109715671B/zh not_active Expired - Fee Related
- 2017-07-21 CA CA3031330A patent/CA3031330C/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020510422A5 (enExample) | ||
| JP2025109785A5 (enExample) | ||
| IL302078A (en) | Anti-CCR8 monoclonal antibodies and their uses | |
| JP2021514664A5 (enExample) | ||
| RU2017105915A (ru) | Антитела против pd-1 | |
| JP2022545660A5 (enExample) | ||
| JP2014530017A5 (enExample) | ||
| JP2017519759A5 (enExample) | ||
| JP2019509976A5 (enExample) | ||
| JP2009545325A5 (enExample) | ||
| RU2014101669A (ru) | Агенты, связывающие белки r-спондины (rspo), и способы их применения | |
| JP2020514277A5 (enExample) | ||
| JP2013523166A5 (enExample) | ||
| JP2018509175A5 (enExample) | ||
| JP2016526904A5 (enExample) | ||
| JP2018504105A5 (enExample) | ||
| RU2010129045A (ru) | Связывающие молекулы к рецептору ох40 человека | |
| RU2019143101A (ru) | Новое анти-с-мет антитело и его применение | |
| JP2024531409A5 (enExample) | ||
| JP2014527814A5 (enExample) | ||
| SI2703486T1 (en) | ANTI-B7-H3 PROTITELO | |
| RU2013152960A (ru) | Анти-cd40-антитела и способы применения | |
| JP2018507188A5 (enExample) | ||
| JP2017521054A5 (enExample) | ||
| JP2023543493A5 (enExample) |